MDMA THERAPY

Sleep rhythm as an early signal in therapy

Many people recovering from depression recognize this: things improve for a while, but old patterns slowly creep back in. Less structure, going to bed later, restless nights, less energy during the day. Therapy often focuses on thoughts, feelings, and behavior, but the circadian rhythm is sometimes an underexposed component. Nevertheless, scientific attention to sleep and biological rhythms as a measurable, early warning signal of relapse is growing.

This article addresses the question: can sleep patterns be measured to predict relapse in depression, and what does this mean practically for therapy and counseling? We also briefly discuss a current research hypothesis: whether psychedelic therapy, such as psilocybin with counseling, might work better if sleep and lifestyle are explicitly taken into account. This is not medical advice or a promise of effect, but an overview of what is and is not substantiated.

What is actigraphy and what exactly do you measure?

Actigraphy is a method in which a person wears a small device, often a watch, that records movement. Using smart algorithms, this movement data can be used to estimate when someone sleeps, how often they wake up, how regular bedtimes are, and how stable the circadian rhythm is. It is not an EEG and therefore not a full sleep measurement like in a sleep lab, but it does provide long-term and relatively objective insight into patterns, often spanning weeks or months.

It is precisely this long-term nature that is interesting for therapy. For example, a client might feel “reasonably” well, while their rhythm has been shifting for weeks. Conversely, someone might feel temporarily depressed, while sleep and rhythm remain stable. Objective data can then help make therapy sessions more concrete, without the data overshadowing the person's experience.

What did the Canadian cohort study show?

A large observational cohort study from Canada followed 93 adults with a history of depression who were relatively stable at baseline. The participants collectively provided approximately 32,000 complete actigraphy days, with a median follow-up of 46 weeks. The researchers investigated whether changes in sleep and circadian rhythms could be associated with later relapse.

Relapse was strictly defined, including by a higher score on a depression scale over several weeks, or other clinical signals such as admission or escalation of treatment. Actigraphy data were collected continuously and summarized at two-week intervals. This is relevant because it concerns trends and stability over time, not a single bad night.

The core finding: less stable sleep and rhythms were associated with a significantly higher risk of relapse. Factors associated with increased risk included lower sleep regularity, lower sleep efficiency, more waking after falling asleep, and more nocturnal activity. One measure stood out particularly strongly: a lower “relative amplitude,” roughly the difference between daytime activity and nighttime rest. In other words: the less clear the contrast between day and night, the higher the risk of relapse in this group.

Important for nuance: this type of research shows associations. It does not prove that poor sleep is the cause of relapse. It could also be the other way around, or there may be a shared underlying factor, such as stress, worrying, medication changes, substance use, or physical complaints. Nevertheless, the clinical implication is interesting: sleep and rhythm can function as “biomarkers” or warning lights that can be monitored in therapy.

More background on this study can be found via the source: Actigraphy study of sleep-rest-activity rhythms as markers for relapse in depression.

What can you do with this in therapy without medicalizing it?

In therapy, sleep tracking can be helpful precisely because it often bridges the gap between “talking” and “doing.” The goal is not to reduce someone to graphs, but to recognize patterns together and time interventions better. A few examples of how this can work in practice:

1) Early detection. If data show that bedtimes are becoming later or that nighttime restlessness is increasing, this may be a reason to discuss stressors, strengthen coping mechanisms, or restore structure, before symptoms escalate.

2) Making goals concrete. “More rest” is vague, whereas “a fixed wake-up time” and “a greater difference between daytime activity and nighttime rest” become measurable and open for discussion. This aligns with many forms of therapy, from CBT to ACT or schema therapy, because it makes behavior and context visible.

3) Normalize and relieve. Some people feel ashamed of recurring symptoms. Data can help show that it often happens in small steps, and that the risk of relapse sometimes first becomes visible in rhythm and recovery, not in 'willpower'.

A word of caution is in order: measuring can cause stress. For people with perfectionism, health anxiety, or sleep performance anxiety, tracking sleep data can actually intensify anxiety. In therapy, it is therefore important to make agreements about how you measure, how often you check, and what conclusions you do and do not draw.

Improving sleep: what is reasonably substantiated?

Apart from actigraphy, there is broader literature indicating that treating insomnia in people with depressive symptoms can, on average, have beneficial effects on mood. In guidelines, cognitive behavioral therapy for insomnia (CBT I) is often cited as the first choice for chronic insomnia. This does not mean that CBT I works for everyone or that it “solves” depression, but it does show that sleep is a serious target within standard treatment.

In practice, this often involves sleep regularity, stimulus control, building up sleep pressure, managing worrying, and maintaining daily structure. Factors such as morning light, sufficient physical activity during the day, and limiting alcohol or other disruptive substances can also be part of the guidance.

And psilocybin or MDMA in therapy: where does sleep fit into the story?

Interest in psychedelics in therapy is growing, particularly in scientific research. For psilocybin, studies show a rapid reduction in depressive symptoms in certain groups, while other trials report mixed outcomes. This underscores that context, preparation, and integration likely make a significant difference. An interesting trend in recent analyses is that people with more severe sleep complaints at baseline may have a lower chance of a favorable outcome, and that residual sleep-related complaints may later be associated with recurring depressive symptoms. This is not yet definitive proof, but it makes the hypothesis logical: if sleep and rhythm are important “prerequisites,” targeted lifestyle coaching regarding sleep can be a valuable addition.

Consequently, the question “does psilocybin plus lifestyle coaching work better?” is currently primarily plausible, but not proven. As far as is known, there is no randomized study that directly compares precisely that combination with psilocybin without sleep-focused coaching. It is therefore a line of reasoning that brings together multiple lines of research, not a single conclusive answer.

Moreover, something different applies to MDMA: MDMA sessions can currently only be discussed within scientific research or in clinical practice in a harm reduction context. In both cases, it is advisable to take sleep and recovery seriously, as an intense experience, emotional processing, and potential after-effects may require extra attention to rhythm, rest, and integration. This is not medical advice, but a general harm reduction consideration.

Practical harm reduction around sleep and rhythm

Whether you are working on recovery in regular therapy or delving into research contexts surrounding psychedelics, sleep often remains a foundation. Some pragmatic points of attention that recur in counseling include: regularity in waking up, sufficient daylight in the morning, realistic planning after intensive therapy sessions, and alertness to substances that disrupt sleep, such as alcohol or stimulants. What is appropriate varies from person to person, and in cases of severe insomnia or suicidal tendencies, professional help is necessary.

Conclusion

Actigraphy research shows that disruption of the sleep and circadian rhythm may be associated with a higher risk of relapse in depression. This is not proof of cause and effect, but it is a useful perspective for therapy: rhythm and sleep continuity can provide early signals and help make guidance more concrete. The hypothesis that psilocybin or other intensive forms of therapy might be more effective when sleep and lifestyle are actively supported is logical and relevant, but not yet definitively proven.

Anyone considering guided sessions for whom harm reduction and integration are important can read up on the content further or discuss a program. You can register via https://mdmatherapie.nl/aanmelden-mdma-sessie/, where it is important to maintain realistic expectations and always carefully consider safety and context.